Genevive Hernandez

1.9k total citations
26 papers, 752 citations indexed

About

Genevive Hernandez is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Genevive Hernandez has authored 26 papers receiving a total of 752 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Immunology. Recurrent topics in Genevive Hernandez's work include Monoclonal and Polyclonal Antibodies Research (15 papers), CAR-T cell therapy research (14 papers) and Biosimilars and Bioanalytical Methods (7 papers). Genevive Hernandez is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (15 papers), CAR-T cell therapy research (14 papers) and Biosimilars and Bioanalytical Methods (7 papers). Genevive Hernandez collaborates with scholars based in United States, South Korea and Canada. Genevive Hernandez's co-authors include Shen Yin, Michael C. Wei, Carol O’Hear, Edward Cha, F. Stephen Hodi, Paul Foster, Hussein A. Tawbi, Sung‐Soo Yoon, Louise Roberts and Jeffrey R. Infante and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Genevive Hernandez

24 papers receiving 730 citations

Peers

Countries citing papers authored by Genevive Hernandez

Since Specialization

Citations

This map shows the geographic impact of Genevive Hernandez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Genevive Hernandez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Genevive Hernandez more than expected).

Fields of papers citing papers by Genevive Hernandez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Genevive Hernandez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Genevive Hernandez. The network helps show where Genevive Hernandez may publish in the future.

Co-authorship network of co-authors of Genevive Hernandez

This figure shows the co-authorship network connecting the top 25 collaborators of Genevive Hernandez. A scholar is included among the top collaborators of Genevive Hernandez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Genevive Hernandez. Genevive Hernandez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death 2025 ·Molecular Cancer Therapeutics ·Robert Yuan, Andrew McGeehan, Sihong Zhou, Christine Cheng, Mark Armanini, Jennifer Smith, Millicent Embry, Rhoneil Pena, Danielle K. Lewis, Genevive Hernandez, Krishna Bajjuri, Cuong Tran, Gang Yin, Cristina L. Abrahams, (unknown), Hans‐Peter Gerber, Alice Yam, Helena Kiefel	1
2	Abstract 1899: Novel combinations of aplitabart, a DR5 agonist IgM antibody, with ADCs or chemotherapeutic agents lead to robust anti-tumor responses in solid tumor models 2024 ·Cancer Research ·Mélanie Desbois, (unknown), Kevin C. Hart, (unknown), (unknown), Thomas J. Matthew, Maya K. Leabman, Sanela Bilic, Genevive Hernandez, Eric W. Humke, Albert F. Candia, Bruce A. Keyt, Angus M. Sinclair, Maya F. Kotturi, (unknown)	1
3	Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL 2023 ·Clinical and Translational Science ·(unknown), Chi‐Chung Li, Kapil Gadkar, Genevive Hernandez, Ling‐Yuh Huw, Jin Y. Jin, Shen Yin, Michael C. Wei, Saroja Ramanujan, Iraj Hosseini	44
4	Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti‐Tumor Activity in a Preclinical Model of Non‐Hodgkin’s Lymphoma 2023 ·Hematological Oncology ·Kathryn Logronio, (unknown), Miho Oyasu, (unknown), (unknown), Genevive Hernandez, Thomas Manley, Angus M. Sinclair, Stephen F. Carroll, Albert F. Candia, Bruce A. Keyt, (unknown)	1
5	Abstract CT125: A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas 2022 ·Cancer Research ·Loretta J. Nastoupil, Lihua E. Budde, Won Seog Kim, Ajay K. Gopal, Chan Y. Cheah, Ian W. Flinn, Gareth P. Gregory, Matthew J. Matasar, Catherine Diefenbach, Matthew Ku, Sung-Soo Yoon, (unknown), (unknown), Maya K. Leabman, Genevive Hernandez, (unknown), Bruce A. Keyt, Thomas Manley, (unknown)	1
6	Abstract 1068: Anti-DR5 agonist IgM antibody IGM-8444 combined with SMAC mimetic birinapant induces strong synergistic tumor cytotoxicity 2022 ·Cancer Research ·(unknown), Mélanie Desbois, (unknown), Thomas J. Matthew, (unknown), Ling Wang, (unknown), (unknown), Miho Oyasu, Maya F. Kotturi, Genevive Hernandez, Xiaohan Liu, Marvin S. Peterson, Eric W. Humke, Bruce A. Keyt, Angus M. Sinclair	2
7	Abstract 4179: High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing 2022 ·Cancer Research ·Kevin C. Hart, Kathryn Logronio, (unknown), (unknown), (unknown), Keyu Li, Paul R. Hinton, Dean Ng, Maya K. Leabman, Genevive Hernandez, Thomas Manley, Angus M. Sinclair, Stephen F. Carroll, Bruce A. Keyt, Maya F. Kotturi	1
8	A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies 2021 ·Blood ·Elizabeth Budde, Ajay K. Gopal, Won Seog Kim, Ian W. Flinn, Chan Y. Cheah, Loretta J. Nastoupil, Matthew J. Matasar, Catherine Diefenbach, Gareth P. Gregory, (unknown), (unknown), Maya K. Leabman, Genevive Hernandez, (unknown), Bruce A. Keyt, Daniel Chen, Philippe Armand	22
9	Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199 2021 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Ling Wang, Thomas J. Matthew, (unknown), Avneesh K. Saini, Maya F. Kotturi, Genevive Hernandez, Eric W. Humke, Marvin S. Peterson, Angus M. Sinclair, Bruce A. Keyt	30
10	841P IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas 2021 ·Annals of Oncology ·(unknown), Maya F. Kotturi, (unknown), (unknown), Paul R. Hinton, Kathryn Logronio, Ramesh Baliga, Genevive Hernandez, Angus M. Sinclair, (unknown), Wayne R. Godfrey, Bruce A. Keyt	1
11	Abstract 52: Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity 2021 ·Cancer Research ·(unknown), (unknown), Kevin C. Hart, (unknown), Mélanie Desbois, (unknown), (unknown), (unknown), Yuan Cao, (unknown), Thomas J. Matthew, Ling Wang, Paul R. Hinton, Maya K. Leabman, Genevive Hernandez, Maya F. Kotturi, Eric W. Humke, Angus M. Sinclair, Bruce A. Keyt	1
12	Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia 2020 ·Cancer Immunology Research ·Patricia E. de Almeida, Judy Mak, Genevive Hernandez, Rajiv Jesudason, Aurélie Hérault, Vincent Javinal, Jovencio Borneo, Jeong Kim, Kevin B. Walsh	80
13	Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients 2019 ·Nature Medicine ·Ryan J. Sullivan, Omid Hamid, René González, Jeffrey R. Infante, Manish R. Patel, F. Stephen Hodi, Karl D. Lewis, Hussein A. Tawbi, Genevive Hernandez, Matthew Wongchenko, (unknown), Louise Roberts, Marcus Ballinger, Yibing Yan, Edward Cha, Patrick Hwu	175
14	Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL 2019 ·Blood ·(unknown), Jinzhen Fan, Christopher R. Bolen, Alexandra Bazeos, Yanwen Jiang, Sandhya Balasubramanian, (unknown), Andrea Knapp, Kathryn Humphrey, Tina Nielsen, Jeffrey M. Venstrom, Genevive Hernandez, Joseph N. Paulson	1
15	An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk 2019 ·Blood ·Catherine Diefenbach, Sarit Assouline, Francesc Bosch, Chan Y. Cheah, Won Seog Kim, Matthew J. Matasar, Carlos Panizo, Dok Hyun Yoon, Brendan C. Bender, Genevive Hernandez, Chi‐Chung Li, Bruce McCall, Carol O’Hear, Michael C. Wei, Shen Yin, Kasra Yousefi, Antonia Kwan, Loretta J. Nastoupil	3
16	Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study 2018 ·Blood ·Lihua E. Budde, Laurie H. Sehn, Sarit Assouline, Ian W. Flinn, Iris Isufi, Sung‐Soo Yoon, Won-Seog Kim, Matthew J. Matasar, Loretta J. Nastoupil, Raoul Santiago, Youngil Koh, Genevive Hernandez, Chi‐Chung Li, (unknown), Bruce McCall, (unknown), Shen Yin, Vinita Gupta, Yu‐Waye Chu, Nancy L. Bartlett	44
17	MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC 2018 ·Journal of Thoracic Oncology ·Charles M. Rudin, Andrés Cervantes, Afshin Dowlati, Benjamin Besse, Brigette Ma, Daniel B. Costa, Peter Schmid, Rebecca S. Heist, Victoria Villaflor, Indrani Sarkar, Genevive Hernandez, Paul Foster, Jessica Spahn, Carol O’Hear, Scott Gettinger	26
18	Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). 2018 ·Journal of Clinical Oncology ·Dong‐Wan Kim, Shirish M. Gadgeel, Scott Gettinger, Gregory J. Riely, Geoffrey R. Oxnard, Tarek Mekhail, Peter Schmid, Afshin Dowlati, Rebecca S. Heist, Antoinette J. Wozniak, Genevive Hernandez, Indrani Sarkar, Emmanuel Mitry, Paul Foster, Carol O’Hear, Jessica Spahn, Sai‐Hong Ignatius Ou	42
19	Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). 2017 ·Journal of Clinical Oncology ·Howard S. Höchster, Johanna C. Bendell, James M. Cleary, Paul Foster, Wei Zhang, Xian He, Genevive Hernandez, Koho Iizuka, S. Gail Eckhardt	62
20	Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma 2016 ·Cancer Research ·Jeffrey J. Wallin, Michael J. Pishvaian, Genevive Hernandez, Mahesh Yadav, Suchit Jhunjhunwala, Lélia Delamarre, Xian He, John D. Powderly, Christopher H. Lieu, Sabine Eckhardt, Herbert I. Hurwitz, Howard S. Höchster, Janet E. Murphy, Vincent Lévêque, Edward Cha, Roel Funke, Daniel Waterkamp, Priti S. Hegde, Johanna C. Bendell	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact